AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 31829521 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental treatment
Number of subjects: 0
Study 31829521 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 31426321 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnesium supplementation (400 mg/day for 3 weeks)
Number of subjects: 18
Study 31426321 — intervention group
Group type: COMPARATOR
Intervention: Control group (no magnesium supplementation)
Number of subjects: 18
Study 28480762 — intervention group
Group type: EXPERIMENTAL
Intervention: 300 mg tenofovir disoproxil fumarate, 300 mg lamivudine, 400/100 mg lopinavir/ritonavir
Number of subjects: 15
Study 28480762 — intervention group
Group type: EXPERIMENTAL
Intervention: 300 mg tenofovir disoproxil fumarate, 300 mg lamivudine, 400 mg nevirapine
Number of subjects: 15
Study 26218728 — intervention group
Group type: EXPERIMENTAL
Intervention: onabotulinumtoxinA (20 U for GL; 24 U for CFL)
Number of subjects: 117
Study 26218728 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 117
Study 26218728 — intervention group
Group type: EXPERIMENTAL
Intervention: onabotulinumtoxinA
Number of subjects: 117
Study 23673092 — intervention group
Group type: EXPERIMENTAL
Intervention: Computer-driven automated weaning system (CDW group)
Number of subjects: 39
Study 23673092 — intervention group
Group type: COMPARATOR
Intervention: Physician-controlled local protocol (PW group)
Number of subjects: 39
Study 21237611 — intervention group
Group type: EXPERIMENTAL
Intervention: Group-based Spanish language educational program facilitated by promotores (12 centers; 161 men)
Number of subjects: 321
Study 21237611 — intervention group
Group type: COMPARATOR
Intervention: Promotores-facilitated diabetes video and discussion (13 centers; 160 men)
Number of subjects: 321
Study 19287011 — intervention group
Group type: EXPERIMENTAL
Intervention: Ganciclovir (6 mg/kg iv every 12 h for 6 weeks)
Number of subjects: 100
Study 19287011 — intervention group
Group type: EXPERIMENTAL
Intervention: Valganciclovir (ongoing trial comparing 6 weeks versus 6 months)
Number of subjects: 100
Study 17596779 — intervention group
Group type: EXPERIMENTAL
Intervention: 1% DEH
Number of subjects: 17
Study 17596779 — intervention group
Group type: EXPERIMENTAL
Intervention: 2% DEH
Number of subjects: 17
Study 17596779 — intervention group
Group type: EXPERIMENTAL
Intervention: 3% DEH
Number of subjects: 17
Study 17596779 — intervention group
Group type: EXPERIMENTAL
Intervention: 4% DEH
Number of subjects: 17
Study 17596779 — intervention group
Group type: EXPERIMENTAL
Intervention: EUH with CES
Number of subjects: 17
Study 17596779 — intervention group
Group type: COMPARATOR
Intervention: EUH control
Number of subjects: 17
Study 15684260 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination group (0.2% ropivacaine and 0.003% morphine)
Number of subjects: 60
Study 15684260 — intervention group
Group type: COMPARATOR
Intervention: Morphine group (0.003% morphine)
Number of subjects: 60
Study 15684260 — intervention group
Group type: COMPARATOR
Intervention: Ropivacaine group (0.2% ropivacaine)
Number of subjects: 60
Study 15684260 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 60
Study 11790702 — intervention group
Group type: EXPERIMENTAL
Intervention: Fenestrated Fontan procedure
Number of subjects: 49
Study 11790702 — intervention group
Group type: COMPARATOR
Intervention: Nonfenestrated Fontan procedure
Number of subjects: 49
Study 10506675 — intervention group
Group type: EXPERIMENTAL
Intervention: Tramadol (200-400 mg/day)
Number of subjects: 45
Study 8708983 — intervention group
Group type: EXPERIMENTAL
Intervention: Orally dissolving tablet (ODT) containing 99mTc‐labelled cholestyramine resin
Number of subjects: 6
Study 8708983 — intervention group
Group type: COMPARATOR
Intervention: 1.5 mL aqueous suspension of 99mTc‐labelled cholestyramine resin
Number of subjects: 6
Study 8708983 — intervention group
Group type: EXPERIMENTAL
Intervention: Both dosage forms (ODT and aqueous suspension)
Number of subjects: 6
Study 8708983 — intervention group
Group type: COMPARATOR
Intervention: Water‐soluble marker
Number of subjects: 6
Study 1960302 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy with recombinant tissue‐type plasminogen activator or urokinase
Number of subjects: 288
Study 1960302 — intervention group
Group type: COMPARATOR
Intervention: Urgent cardiac catheterization
Number of subjects: 288
Study 1960302 — intervention group
Group type: COMPARATOR
Intervention: Mean left ventricular ejection fraction
Number of subjects: 288
Study 1960302 — intervention group
Group type: COMPARATOR
Intervention: Regional infarct zone wall motion
Number of subjects: 288
Study 7139504 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled powder (200 micrograms)
Number of subjects: 10
Study 7139504 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled powder (400 micrograms)
Number of subjects: 10
Study 7139504 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerosol (200 micrograms)
Number of subjects: 10
Study 7139504 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 31893232 — intervention group
Group type: EXPERIMENTAL
Intervention: HIV-positive participants
Number of subjects: 250
Study 31893232 — intervention group
Group type: COMPARATOR
Intervention: HIV-negative participants
Number of subjects: 250
Study 31893232 — intervention group
Group type: EXPERIMENTAL
Intervention: 18F-FDG PET/CT
Number of subjects: 250
Study 29458116 — intervention group
Group type: EXPERIMENTAL
Intervention: Food cues (exposure to food advertising)
Number of subjects: 98
Study 29458116 — intervention group
Group type: COMPARATOR
Intervention: Non-food cues (exposure to neutral advertising)
Number of subjects: 98
Study 26702843 — intervention group
Group type: EXPERIMENTAL
Intervention: 25-gauge vitrectomy with 7,500 cuts per minute (cpm) probes (7,500 Group)
Number of subjects: 62
Study 26702843 — intervention group
Group type: COMPARATOR
Intervention: 25-gauge vitrectomy with 5,000 cpm probes (Standard Group)
Number of subjects: 62
Study 26702843 — intervention group
Group type: COMPARATOR
Intervention: Comparison of core vitrectomy duration between 7,500 Group and Standard Group
Number of subjects: 62
Study 26702843 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 62
Study 24787497 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight-management (diet)
Number of subjects: 107
Study 24787497 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise
Number of subjects: 107
Study 24787497 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight-management-plus-exercise (diet-exercise)
Number of subjects: 107
Study 24787497 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 107
Study 24787497 — intervention group
Group type: EXPERIMENTAL
Intervention: Geriatric Depression Scale (GDS)
Number of subjects: 107
Study 22726220 — intervention group
Group type: EXPERIMENTAL
Intervention: Canakinumab
Number of subjects: 190
Study 22726220 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 190
Study 20679260 — intervention group
Group type: EXPERIMENTAL
Intervention: Systematic Treatment Selection (STS) for Psychodynamic Therapy (PDT)
Number of subjects: 291
Study 20679260 — intervention group
Group type: COMPARATOR
Intervention: Random Treatment Selection (RTS) for Psychodynamic Therapy (PDT)
Number of subjects: 291
Study 20679260 — intervention group
Group type: EXPERIMENTAL
Intervention: Systematic Treatment Selection (STS) for Cognitive-Behavioural Therapy (CBT)
Number of subjects: 291
Study 20679260 — intervention group
Group type: COMPARATOR
Intervention: Random Treatment Selection (RTS) for Cognitive-Behavioural Therapy (CBT)
Number of subjects: 291
Study 17991054 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group
Number of subjects: 100
Study 17991054 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 100
Study 16368054 — intervention group
Group type: EXPERIMENTAL
Intervention: RSG 4 mg/day (increased to 8 mg/day) + MET 1000 mg/day (total 1500 mg/day)
Number of subjects: 766
Study 16368054 — intervention group
Group type: COMPARATOR
Intervention: MET 500 mg/day (increased to 2000 mg/day)
Number of subjects: 766
Study 16368054 — intervention group
Group type: EXPERIMENTAL
Intervention: RSG + MET
Number of subjects: 766
Study 12390439 — intervention group
Group type: EXPERIMENTAL
Intervention: Exclusive breast-feeding for at least 4 months
Number of subjects: 1121
Study 12390439 — intervention group
Group type: COMPARATOR
Intervention: Partially or exclusively formula-fed
Number of subjects: 1121
Study 12390439 — intervention group
Group type: EXPERIMENTAL
Intervention: Infants with AD
Number of subjects: 1121
Study 12390439 — intervention group
Group type: EXPERIMENTAL
Intervention: Age at first introduction of solid food and diversity of solid food
Number of subjects: 1121
Study 9801962 — intervention group
Group type: EXPERIMENTAL
Intervention: Panic disorder
Number of subjects: 99
Study 9801962 — intervention group
Group type: COMPARATOR
Intervention: Social phobia
Number of subjects: 99
Study 9801962 — intervention group
Group type: COMPARATOR
Intervention: Nonanxious controls
Number of subjects: 99
Study 8521882 — intervention group
Group type: EXPERIMENTAL
Intervention: Carvedilol 25 mg b.i.d for 2 weeks followed by 50 mg b.i.d for a further 2 weeks
Number of subjects: 23
Study 8521882 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous carvedilol followed by oral carvedilol 50 mg b.i.d for 8 weeks
Number of subjects: 23
Study 2677532 — intervention group
Group type: EXPERIMENTAL
Intervention: Carotid endarterectomy
Number of subjects: 945
Study 2677532 — intervention group
Group type: COMPARATOR
Intervention: Aspirin, 80 mg/day
Number of subjects: 945
Study 355043 — intervention group
Group type: EXPERIMENTAL
Intervention: Esophatrast
Number of subjects: 0
Study 355043 — intervention group
Group type: EXPERIMENTAL
Intervention: Barosperse Esophageal Paste
Number of subjects: 0
Study 355043 — intervention group
Group type: EXPERIMENTAL
Intervention: HD‐5000
Number of subjects: 0
Study 29934249 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 mA tDCS administered for 10 sessions of 20 minutes each on five consecutive days (two sessions per day)
Number of subjects: 54
Study 29934249 — intervention group
Group type: COMPARATOR
Intervention: Placebo administered for 10 sessions of 20 minutes each on five consecutive days (two sessions per day)
Number of subjects: 54
Study 29934249 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 mA tDCS
Number of subjects: 54
Study 29934249 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 54
Study 27221140 — intervention group
Group type: EXPERIMENTAL
Intervention: Volume-Controlled Ventilation
Number of subjects: 41
Study 27221140 — intervention group
Group type: COMPARATOR
Intervention: Pressure-Controlled Ventilation
Number of subjects: 41
Study 24652107 — intervention group
Group type: EXPERIMENTAL
Intervention: Varenicline 1 mg
Number of subjects: 0
Study 24652107 — intervention group
Group type: COMPARATOR
Intervention: Matched placebo
Number of subjects: 0
Study 22430640 — intervention group
Group type: EXPERIMENTAL
Intervention: Streaming weekly soap opera video episodes to smartphones
Number of subjects: 238
Study 22430640 — intervention group
Group type: COMPARATOR
Intervention: Weekly HIV risk reduction written messages to smartphones
Number of subjects: 238
Study 20450672 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspherical IOL
Number of subjects: 436
Study 20450672 — intervention group
Group type: COMPARATOR
Intervention: Spherical IOL
Number of subjects: 436
Study 18304620 — intervention group
Group type: EXPERIMENTAL
Intervention: Yttrium‐90‐labeled human milk fat globule 1 murine monoclonal antibody (90Y‐muHMFG1)
Number of subjects: 447
Study 18304620 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment (control group)
Number of subjects: 447
Study 18304620 — intervention group
Group type: EXPERIMENTAL
Intervention: Affinity chromatography of serum samples with high CA 125 values
Number of subjects: 447
Study 15830972 — intervention group
Group type: EXPERIMENTAL
Intervention: Percutaneous cervical nucleoplasty using coblation technology
Number of subjects: 50
Study 15830972 — intervention group
Group type: COMPARATOR
Intervention: Conservative treatment with medical and physical therapy
Number of subjects: 50
Study 14559420 — intervention group
Group type: EXPERIMENTAL
Intervention: Cold environment (5 degrees C)
Number of subjects: 50
Study 14559420 — intervention group
Group type: EXPERIMENTAL
Intervention: Warm environment (35 degrees C)
Number of subjects: 50
Study 14559420 — intervention group
Group type: COMPARATOR
Intervention: No control over temperature
Number of subjects: 50
Study 14559420 — intervention group
Group type: EXPERIMENTAL
Intervention: Thermoneutral environment (20 degrees C)
Number of subjects: 50
Study 10484900 — intervention group
Group type: EXPERIMENTAL
Intervention: H2 receptor antagonists (Group A)
Number of subjects: 192
Study 10484900 — intervention group
Group type: COMPARATOR
Intervention: Placebo (Group B)
Number of subjects: 192
Study 9085534 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral appliance therapy (OA)
Number of subjects: 0
Study 9085534 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjustable oral appliances (OA)
Number of subjects: 0
Study 9085534 — intervention group
Group type: COMPARATOR
Intervention: Nasal CPAP
Number of subjects: 0
Study 1751444 — intervention group
Group type: EXPERIMENTAL
Intervention: Low sodium diet (20 mmol sodium daily)
Number of subjects: 42
Study 1751444 — intervention group
Group type: COMPARATOR
Intervention: Unrestricted sodium intake
Number of subjects: 42
Study 7128187 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.5 g glucosamine sulphate daily
Number of subjects: 40
Study 7128187 — intervention group
Group type: COMPARATOR
Intervention: 1.2 g ibuprofen daily
Number of subjects: 40
Study 31557755 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-reported acne vulgaris (AV)
Number of subjects: 714
Study 31557755 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical examination for acne vulgaris (AV)
Number of subjects: 714
Study 31557755 — intervention group
Group type: COMPARATOR
Intervention: Gender (female vs male)
Number of subjects: 714
Study 31557755 — intervention group
Group type: COMPARATOR
Intervention: BMI categories (overweight/obese vs normal weight)
Number of subjects: 714
Study 31017456 — intervention group
Group type: EXPERIMENTAL
Intervention: Trigger point dry needling (TrP‐DN) of sternocleidomastoid
Number of subjects: 34
Study 31017456 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 34
Study 30567694 — intervention group
Group type: EXPERIMENTAL
Intervention: Participatory ergonomics intervention with technical measurements (IMUs, sEMG, heart rate monitoring, video recordings)
Number of subjects: 80
Study 30567694 — intervention group
Group type: EXPERIMENTAL
Intervention: Participatory ergonomics intervention
Number of subjects: 80
Study 30567694 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 80
Study 27707497 — intervention group
Group type: EXPERIMENTAL
Intervention: Clear-lens extraction
Number of subjects: 419
Study 27707497 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 419
Study 27707497 — intervention group
Group type: COMPARATOR
Intervention: Clear-lens extraction vs Standard care
Number of subjects: 419
Study 25799845 — intervention group
Group type: EXPERIMENTAL
Intervention: Smoking group
Number of subjects: 85
Study 25799845 — intervention group
Group type: COMPARATOR
Intervention: Tobacco-abstinent group
Number of subjects: 85
Study 22425689 — intervention group
Group type: EXPERIMENTAL
Intervention: Microencapsulated Lactobacillus reuteri NCIMB 30242 in yogurt, 5 × 10(10) CFU, twice/day for 6 weeks
Number of subjects: 120
Study 22425689 — intervention group
Group type: COMPARATOR
Intervention: Placebo yogurt
Number of subjects: 120
Study 22425689 — intervention group
Group type: EXPERIMENTAL
Intervention: Microencapsulated Lactobacillus reuteri NCIMB 30242 in yogurt
Number of subjects: 120
Study 20717800 — intervention group
Group type: EXPERIMENTAL
Intervention: Visuomotor adaptation with a misaligned cursor rotated 30 degrees clockwise
Number of subjects: 0
Study 20717800 — intervention group
Group type: EXPERIMENTAL
Intervention: Visuomotor adaptation
Number of subjects: 0
Study 20717800 — intervention group
Group type: EXPERIMENTAL
Intervention: Proprioceptive recalibration
Number of subjects: 0
Study 18853556 — intervention group
Group type: EXPERIMENTAL
Intervention: Kanizsa square-like rivalry displays with vertical illusory contours
Number of subjects: 0
Study 18853556 — intervention group
Group type: EXPERIMENTAL
Intervention: Manipulated stimulus conditions (switching half-images, relocating pacmen, placing pacmen diagonally)
Number of subjects: 0
Study 18853556 — intervention group
Group type: COMPARATOR
Intervention: 135 degree-grating disc in rivalry with a 135 degree-grating pacman on a 45 degree-grating background
Number of subjects: 0
Study 18853556 — intervention group
Group type: EXPERIMENTAL
Intervention: Alignment of images in the two eyes
Number of subjects: 0
Study 15807452 — intervention group
Group type: EXPERIMENTAL
Intervention: Colloid bismuth subcitrate (CBS) 240 mg twice a day + amoxicillin 2 g/day and furozolidon 400 mg/day (subgroup 1a, n = 10)
Number of subjects: 45
Study 15807452 — intervention group
Group type: EXPERIMENTAL
Intervention: Colloid bismuth subcitrate (CBS) monotherapy 240 mg twice a day (subgroup 1b, n = 20)
Number of subjects: 45
Study 15807452 — intervention group
Group type: COMPARATOR
Intervention: Ranitidine 150 mg twice a day (group 2, n = 15)
Number of subjects: 45
Study 12058489 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitrectomy without the use of microscissors
Number of subjects: 24
Study 12058489 — intervention group
Group type: COMPARATOR
Intervention: Vitrectomy with the use of microscissors
Number of subjects: 24
Study 10703658 — intervention group
Group type: EXPERIMENTAL
Intervention: Guidor Matrix Barrier (membrane placement)
Number of subjects: 16
Study 10703658 — intervention group
Group type: COMPARATOR
Intervention: Conventional flap surgery only
Number of subjects: 16
Study 9505333 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasonic debridement with 24% EDTA solution as irrigation agent
Number of subjects: 24
Study 9505333 — intervention group
Group type: COMPARATOR
Intervention: Conventional application of irrigation fluid
Number of subjects: 24
Study 8475962 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetaminophen (1000 mg)
Number of subjects: 6
Study 8475962 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study 8475962 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetaminophen (10 micrograms/ml)
Number of subjects: 6
Study 8475962 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetaminophen (100 micrograms/ml)
Number of subjects: 6
Study 8475962 — intervention group
Group type: EXPERIMENTAL
Intervention: Indomethacin (10 micrograms/ml)
Number of subjects: 6
Study 3092657 — intervention group
Group type: EXPERIMENTAL
Intervention: Enprostil 70 micrograms twice daily
Number of subjects: 128
Study 3092657 — intervention group
Group type: EXPERIMENTAL
Intervention: Enprostil 35 micrograms twice daily
Number of subjects: 128
Study 3092657 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 128
Study 3092657 — intervention group
Group type: EXPERIMENTAL
Intervention: Enprostil 70 micrograms twice daily (in smokers)
Number of subjects: 128
Study 3092657 — intervention group
Group type: EXPERIMENTAL
Intervention: Enprostil 35 micrograms twice daily (in smokers)
Number of subjects: 128
Study 3092657 — intervention group
Group type: COMPARATOR
Intervention: Placebo (in smokers)
Number of subjects: 128
Study 31450067 — intervention group
Group type: COMPARATOR
Intervention: Regular rhythm track
Number of subjects: 0
Study 31450067 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderately syncopated rhythm track
Number of subjects: 0
Study 31450067 — intervention group
Group type: EXPERIMENTAL
Intervention: Highly syncopated rhythm track
Number of subjects: 0
Study 29095191 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasonic Doppler monitoring of popliteal artery blood flow; tourniquet pressure set until maximum systolic velocity reduced to 0.
Number of subjects: 96
Study 29095191 — intervention group
Group type: COMPARATOR
Intervention: Standard tourniquet pressure determined by doctor's request, not exceeding 80 KPa.
Number of subjects: 96
Study 28477505 — intervention group
Group type: EXPERIMENTAL
Intervention: BRAVE‐ONLINE (NET)
Number of subjects: 42
Study 28477505 — intervention group
Group type: COMPARATOR
Intervention: Waitlist Control (WLC)
Number of subjects: 42
Study 26233499 — intervention group
Group type: EXPERIMENTAL
Intervention: 80 mg intraarticular triamcinolone acetonide
Number of subjects: 97
Study 26233499 — intervention group
Group type: COMPARATOR
Intervention: 40 mg intraarticular triamcinolone acetonide
Number of subjects: 97
Study 24264552 — intervention group
Group type: EXPERIMENTAL
Intervention: Pregabaline 150 mg 1 hr before operation and 75 mg 12 hr after operation
Number of subjects: 60
Study 24264552 — intervention group
Group type: COMPARATOR
Intervention: Placebo empty capsule
Number of subjects: 60
Study 21393587 — intervention group
Group type: EXPERIMENTAL
Intervention: Implementation strategy (5 meetings based on the Breakthrough Series model)
Number of subjects: 5515
Study 21393587 — intervention group
Group type: COMPARATOR
Intervention: Control (no implementation strategy)
Number of subjects: 5515
Study 18942248 — intervention group
Group type: EXPERIMENTAL
Intervention: Sufentanil 0.1 microg/kg (Group S)
Number of subjects: 60
Study 18942248 — intervention group
Group type: COMPARATOR
Intervention: Pethidine 1.5 mg/kg (Group P)
Number of subjects: 60
Study 16798309 — intervention group
Group type: EXPERIMENTAL
Intervention: BioGlue (surgical treatment and BioGlue)
Number of subjects: 52
Study 16798309 — intervention group
Group type: COMPARATOR
Intervention: Control (surgical treatment only)
Number of subjects: 52
Study 12678218 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorthalidone
Number of subjects: 0
Study 12678218 — intervention group
Group type: COMPARATOR
Intervention: Amlodipine
Number of subjects: 0
Study 12678218 — intervention group
Group type: COMPARATOR
Intervention: Lisinopril
Number of subjects: 0
Study 12678218 — intervention group
Group type: COMPARATOR
Intervention: Doxazosin
Number of subjects: 0
Study 11077224 — intervention group
Group type: EXPERIMENTAL
Intervention: Mycophenolate mofetil (MMF) therapy
Number of subjects: 38
Study 9372290 — intervention group
Group type: EXPERIMENTAL
Intervention: Constant acceleration, constant deceleration, and constant velocity targets with motion times from 0.5 to 2.0 s
Number of subjects: 2614
Study 9372290 — intervention group
Group type: EXPERIMENTAL
Intervention: Threshold-distance model
Number of subjects: 2614
Study 9372290 — intervention group
Group type: EXPERIMENTAL
Intervention: Threshold-tau model
Number of subjects: 2614